Rivaroxaban: A New Oral Factor Xa Inhibitor
- 1 March 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 30 (3), 376-381
- https://doi.org/10.1161/atvbaha.110.202978
Abstract
Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the blood coagulation pathway leading to thrombin generation and clot formation. It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (half-maximal inhibitory concentration [IC50], >20 μmol/L). Rivaroxaban inhibits factor Xa in a concentration-dependent manner (inhibitory constant [Ki], 0.4 nmol/L) and binds rapidly (kinetic association rate constant [kon], 1.7×107 mol/L−1 s−1) and reversibly (kinetic dissociation rate constant [koff], 5×10−3 s−1). By inhibiting prothrombinase complex-bound (IC50, 2.1 nmol/L) and clot-associated factor Xa (IC50, 75 nmol/L), rivaroxaban reduces the thrombin burst during the propagation phase. In animal models of venous and arterial thrombosis, rivaroxaban showed dose-dependent antithrombotic activity. In healthy individuals, rivaroxaban was found to have predictable pharmacokinetics and pharmacodynamics across a 5- to 80-mg total daily dose range, inhibiting factor Xa activity and prolonging plasma clotting time. In phase III clinical trials, rivaroxaban regimens reduced rates of venous thromboembolism in patients after total hip or knee arthroplasty compared with enoxaparin regimens, without significant differences in rates of major bleeding, showing that rivaroxaban has a favorable benefit-to-risk profile.Keywords
This publication has 38 references indexed in Scilit:
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitorThrombosis and Haemostasis, 2010
- Mechanisms of Thrombus FormationNew England Journal of Medicine, 2008
- New Antithrombotic DrugsChest, 2008
- Factor Xa or thrombin: is factor Xa a better target?Journal of Thrombosis and Haemostasis, 2007
- In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxabanJournal of Thrombosis and Haemostasis, 2007
- Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa InhibitorJournal of Medicinal Chemistry, 2005
- Ximelagatran and melagatran vs. low‐molecular‐weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administrationJournal of Thrombosis and Haemostasis, 2005
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005
- Effects of ZK-807834, a Novel Inhibitor of Factor Xa, on Arterial and Venous Thrombosis in RabbitsJournal of Cardiovascular Pharmacology, 2000
- Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitorThrombosis Research, 1995